Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,153 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Regimen B Clear all
Completed Phase 2 Interventional Results available

Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant

NCT01754389
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Tacrolimus, Methotrexate, Bortezomib, Sirolimus
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Sep 3, 2026, 8:43 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT05668013
View directory record Official record
Conditions
Crohn Disease, Colitis, Ulcerative
Interventions
TEV-48574 Dose Regimen A, TEV-48574 Dose Regiment B
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
18
States / cities
San Diego, California • Kissimmee, Florida • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

NCT00075946
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
483
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 328 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 3, 2026, 8:43 AM EDT
Recruiting Phase 2 Interventional

Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

NCT06849713
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL)
Interventions
Zanubrutinib, Sonrotoclax, Obinutuzumab, Tacabrutideg
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen B Verdiperstat

NCT04436510
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Matching Placebo, Verdiperstat
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

NCT02360579
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Lifileucel
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

NCT03786783
View directory record Official record
Conditions
Ganglioneuroblastoma, High Risk Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Dexrazoxane, Dinutuximab, Doxorubicin, Etoposide, External Beam Radiation Therapy, Isotretinoin, Melphalan, Sargramostim, Thiotepa, Topotecan, Vincristine
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

NCT02563327
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifapentine, Moxifloxacin, Rifampin, Isoniazid, Pyrazinamide, Ethambutol, Pyridoxine
Drug · Dietary Supplement
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
2,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 3, 2026, 8:43 AM EDT
Terminated Phase 1 Interventional

A Study of ASP2074 in Adults With Solid Tumors

NCT05646797
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ASP2074
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Sacramento, California • Iowa City, Iowa • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010

NCT03311373
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Regimen A, Regimen B, Regimen C, Regimen D
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 3, 2026, 8:43 AM EDT
Active, not recruiting Phase 1 Interventional

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

NCT01044069
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia
Interventions
gene-modified T cells targeted
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers

NCT00647868
View directory record Official record
Conditions
Hypogonadism
Interventions
testosterone
Drug
Lead sponsor
Acerus Pharmaceuticals Corporation
Industry
Eligibility
20 Years to 60 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Sep 3, 2026, 8:43 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05259839
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Etentamig, Dexamethasone, Lenalidomide, Pomalidomide, Daratumumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
15
States / cities
Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 3, 2026, 8:43 AM EDT
Not listed Phase 2 Interventional

Reducing Proviral HIV DNA With Interferon-a

NCT02227277
View directory record Official record
Conditions
HIV, HIV/AIDS
Interventions
Peg-IFN-α2b
Drug
Lead sponsor
The Wistar Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

NCT00783367
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue, Lymphoma, Small Lymphocytic, Waldenstrom Macroglobulinemia, Mantle-Cell Lymphoma
Interventions
Lenalidomide, Dexamethasone, Rituximab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 3, 2026, 8:43 AM EDT
Active, not recruiting Phase 2 Interventional

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma

NCT03323463
View directory record Official record
Conditions
HPV-Associated Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Neck
Interventions
F-FMISO PET/CT Scan, 30 Gy over 3 weeks, Cisplatin, Carboplatin, 5Fluorouracil, Proton Therapy
Diagnostic Test · Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 3, 2026, 8:43 AM EDT
Terminated Phase 2 Interventional Results available

To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).

NCT04253236
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia
Interventions
RVT-1401 680 mg/weekly, RVT-1401 340 mg/weekly
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Iowa City, Iowa • Louisville, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

Belatacept Pharmacokinetic Trial in Renal Transplantation

NCT00578448
View directory record Official record
Conditions
Renal Transplantation
Interventions
Belatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Springfield, Massachusetts • Detriot, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 3, 2026, 8:43 AM EDT
Terminated Phase 2 Interventional Results available

Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma

NCT00031590
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors, Medulloblastoma
Interventions
Cisplatin, Cyclophosphamide, Etoposide, Lomustine, Vincristine, Craniospinal Radiation
Drug · Radiation
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
3 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
3
States / cities
Palo Alto, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 3, 2026, 8:43 AM EDT
Terminated Phase 2 Interventional Results available

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

NCT00126191
View directory record Official record
Conditions
Burkitt Lymphoma, Non-Hodgkins Lymphoma, Atypical Burkitt Lymphoma
Interventions
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Methotrexate, Leucovorin, Ifosfamide, Etoposide, Cytarabine, Mesna
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 4 Interventional Results available

Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM

NCT04039217
View directory record Official record
Conditions
ART, HIV
Interventions
Biktarvy
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Sep 3, 2026, 8:43 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

NCT06111235
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Interventions
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
Drug · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
90
States / cities
Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone

NCT00265317
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
erlotinib, sunitinib, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Antioch, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Sep 3, 2026, 8:43 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus

NCT03333317
View directory record Official record
Conditions
Respiratory Syncytial Viruses
Interventions
Lumicitabine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
28 Days to 36 Months
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Long Beach, California • Kansas City, Missouri • Syracuse, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Sep 3, 2026, 8:43 AM EDT